Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 28 of 115, showing 5 Applications out of 571 total, starting on record 136, ending on 140

# Protocol No Study Title Investigator(s) & Site(s)

136.

ECCT/24/02/03   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with   Uncomplicated Plasmodium falciparum Malaria       
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
View

137.

ECCT/23/11/05   Alma Study
    Feasibility clinical study of the Alma system in treating Primary Postpartum Hemorrhage - Alma Study    
Principal Investigator(s)
1. Omondi Ogutu
Site(s) in Kenya
Kenyatta National Hospital
 
View

138.

ECCT/23/11/06   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
View

139.

ECCT/23/11/01   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. AHERO CLINICAL TRIALS UNIT (Kisumu county)
3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
 
View

140.

ECCT/23/11/04   AUB Study
    A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.   
Principal Investigator(s)
1. Dr Alice Kaaria
Site(s) in Kenya
Kenyatta National Hospital (KNH)
 
View